Medulloblastoma

This phase 2 trial tests whether the immunotherapy drug nivolumab can shrink tumors or slow their growth in adults with rare central nervous system (brain or spine) tumors that have returned after prior treatment. Participants receive nivolumab by IV every 2 to 4 weeks for up to …

This study tested an oral drug called CX-4945 (silmitasertib) in 21 children with recurrent SHH medulloblastoma, a rare brain tumor. The trial aimed to find the best dose and see if the drug could shrink tumors. However, the study was stopped early, so we don't have clear answers…

This phase 2 trial tested a personalized treatment approach for post-pubertal patients with newly diagnosed medulloblastoma, a rare brain cancer. The experimental group received a targeted drug called sonidegib along with reduced radiation, based on the tumor's genetic subtype. T…

This early-phase trial tested a combination of three drugs—ribociclib, topotecan, and temozolomide—in children with relapsed or refractory neuroblastoma and other solid tumors. The goal was to find a safe dose and see if the combination could shrink tumors. Only 12 children took …

This study looked at whether a liquid biopsy—testing the fluid around the brain and spinal cord—can find tumor DNA in children and young adults with brain tumors. The goal was to see if this safer, non-surgical test could replace risky tissue biopsies for diagnosis and monitoring…

This study looked at stored tumor samples from 139 children with brain and central nervous system tumors. Researchers wanted to find DNA changes and biomarkers that could help understand these cancers better. The study was terminated early, so results may be limited.